Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Efficacy of high-dose liraglutide 3.0 mg in patients with poor response to bariatric surgery: real-world experience and updated meta-analysis
The Food Institute Podcast Is it possible to balance a legacy brand and innovative ideas for a food company
After the initial introduction of SGLT2i in 2013 [9] and following demonstration of kidney and cardiovascular outcome benefits for patients with type 2 diabetes, in 2021 the US Food and Drug Administration (FDA) provided the first indication that SGLT2i reduced the risk of kidney disease progression in patients with CKD [10, 11]
Glucagon-like peptide-1 receptor agonist Exendin-4 improves neurological outcomes by attenuating TBI- induced inflammatory responses and MAPK activation in rats
US$ 24.70
US$ 26.78
US$ 20.99
US$ 23.79
